CBS 2019
CBSMD教育中心
English

充血性心力衰竭

科研文章

荐读文献

Dapagliflozin Effects on Biomarkers, Symptoms, and Functional Status in Patients With Heart Failure With Reduced Ejection Fraction: The DEFINE-HF Trial Effect of Empagliflozin on Cardiovascular and Renal Outcomes in Patients With Heart Failure by Baseline Diabetes Status - Results from the EMPEROR-Reduced Trial Vericiguat in Patients with Heart Failure and Reduced Ejection Fraction Cardiovascular Aging and Heart Failure: JACC Review Topic of the Week Left Ventricular Assist Devices: Synergistic Model Between Technology and Medicine Vaccination Trends in Patients With Heart Failure - Insights From Get With The Guidelines–Heart Failure Antithrombotics From Aspirin to DOACs in Coronary Artery Disease and Atrial Fibrillation (Part 3/5) Ejection Fraction Pros and Cons: JACC State-of-the-Art Review Clinical epidemiology of heart failure with preserved ejection fraction (HFpEF) in comparatively young hospitalized patients Heart Failure With Preserved Ejection Fraction in the Young
|<< 1 2 3 4 5 6 7 ...>>|

Clinical TrialNovember 10, 2018

JOURNAL：N Engl J Med. Article Link

Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes

SD Wiviott，I Raz，DECLARE–TIMI 58 Investigators. Keywords: Diabetes and Cardiometabolic Disease, Dyslipidemia, Heart Failure and Cardiomyopathies, Prevention, Acute Heart Failure, Hypertension, Smoking

FULL TEXT PDF

>CBS CBS 2019

> CBS 2019

> CBS 2019 注册

> CBS 2019 会议日程

> CBS 2019 学术征集

> CBS 2019 热点

 CBSMD

> CBSMD 网站注册

> 教育中心

> 荐读文献

> Top 10 阅读文献

> 文献导读
CBS 2019 CBS 2019 主席团 教育中心 科研动态
Copyright ⓒ CBS MD Nanjing China. All rights reserved. 京ICP备16025898号-11
联系我们| Top